Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
Cancer Research|May 19, 2005
Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesisYi Tang, Varalakshmi Katuri, Radhika Srinivasan, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 12, 2014
B-myb is an essential regulator of hematopoietic stem cell and myeloid progenitor cell developmentStacey J Baker, Avi Ma'ayan, Yen K Lieu, et al.
Molecular Cell|July 4, 2020
A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding AgentStacey J Baker, Stephen C Cosenza, Saikrishna Athuluri-Divakar, et al.
Journal of Medicinal Chemistry|December 20, 2007
Design, synthesis, and biological evaluation of (E)-styrylbenzylsulfones as novel anticancer agentsM V Ramana Reddy, Muralidhar R Mallireddigari, Stephen C Cosenza, et al.
Journal of Medicinal Chemistry|August 5, 2011
Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activityM V Ramana Reddy, Padmavathi Venkatapuram, Muralidhar R Mallireddigari, et al.
Cancer Cell|March 16, 2005
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agentKiranmai Gumireddy, M V Ramana Reddy, Stephen C Cosenza, et al.
Pharmaceutics|December 28, 2021
Posiphen Reduces the Levels of Huntingtin Protein through Translation SuppressionXu-Qiao Chen, Carlos A Barrero, Rodrigo Vasquez-Del Carpio, et al.
Bioorganic & Medicinal Chemistry|March 2, 2010
Design, synthesis and evaluation of (E)-alpha-benzylthio chalcones as novel inhibitors of BCR-ABL kinaseM V Ramana Reddy, Venkat R Pallela, Stephen C Cosenza, et al.
Radiation Research|March 10, 2009
Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanismsSanchita P Ghosh, Michael W Perkins, Kevin Hieber, et al.
Oncotarget|February 1, 2019
Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemiaAmol Padgaonkar, Olga Rechkoblit, Rodgrigo Vasquez-Del Carpio, et al.
Pageof 11